Virus Peptides TRIZ Cases

Expressing a phage protein inhibits bacterial host cell growth, reducing metabolic burden and oxygen demand while increasing recombinant protein yield.

Removing the K4L gene eliminates immunosuppression, allowing poxviruses to trigger strong interferon and cytokine responses without viral interference.

Novel chimeric AAV capsids alter tropism profiles through targeted amino acid substitutions in beta-sheet loop regions.

Peptide n-mers on a biopolymer scaffold bind viral capsid proteins to deplete neutralizing antibody titers, restoring gene therapy vector efficacy.

Culturing mammalian cells with dimethyl sulfoxide and elevated temperatures boosts recombinant adeno-associated virus particle yields.

Recombinant HAP2 antigens trigger host immunity to block Babesia transmission, avoiding toxicity and resistance risks from chemical acaricides.

A site-specific unidirectional recombinase mediates precise recombination between genomic and plasmid sites to introduce stable genetic variants into mammalian cell lines.

Modified adenoviral capsid proteins enable modular antigen display via covalent peptide bonds, evading neutralizing antibodies while retaining infectivity.

Specific amino acid substitutions in the AAV capsid reduce liver toxicity while maintaining muscle transduction efficiency.

Segmenting baculovirus vectors prevents homologous recombination, stabilizing production yields while maintaining high titers.

In vitro stimulation of T cells using antigen-presenting cells matched to individual HLA haplotypes.

Assembling peptides that mimic structural epitopes to enhance antibody assay sensitivity and stability.

Amino acid substitutions in AAVrh74 capsids reduce liver sequestration, increasing the availability of viral vectors for effective muscle gene delivery.

In vitro conjugation attaches retargeting ligands to adeno-associated virus capsids through covalent bonding.

A recombinant AAV library production process links phenotype to genotype through segmented capsid expression.

Single-locus integration of AAV genes eliminates wild-type adenovirus contamination and reduces production costs for gene therapy applications.

Consolidated plasmid provides essential helper functions while eliminating residual adenovirus production and associated immune responses.

A culture medium containing transition metals and cysteine protease inhibitors increases VP1 and VP3 protein incorporation into rAAV capsids.

Engineered dESV40 promoters enable rapid identification of high-yield mammalian cell lines, shortening development time for therapeutic antibody production.

Multiple anion exchange chromatography passes enrich full adeno-associated virus capsids from empty variants.

Conditional mutagenesis lowers error catastrophe risks while maintaining high evolutionary speed for protein engineering.

Simian adenovirus vectors deliver heterologous genes while evading neutralizing antibodies from prior exposure.

Segmented cell-free synthesis and bioorthogonal conjugation form multimeric polypeptides while preserving enzymatic activity lost in traditional cloning.

Disulfide bridges at positions 970 and 999 lock the prefusion conformation, preventing transition to the postfusion state without rigidifying the central helix.